Expansion of the pharmaceutical network membership base
First written in FY2016. 30 of 31 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「As of 31 March 2026, the pharmaceutical network had 12,003 member locations, comprising 472 locations operated by the Group and 11,531 general member stores, an increase of 1,000 from the end of the previous consolidated fiscal year.」
The pharmaceutical network membership base increased from 11,003 at the end of the previous fiscal year to 12,003, exceeding 12,000. - FY2026-H1AdvancedAnnual report
「As of 30 September 2025, the pharmaceutical network had 11,511 member locations, comprising 469 locations operated by the Group and 11,042 general member stores, an increase of 508 from the end of the previous consolidated fiscal year.」
The pharmaceutical network membership base increased from 11,003 at the end of the previous fiscal year to 11,511. - FY2025-H1AdvancedAnnual report
「As of 30 September 2024, the pharmaceutical network had 10,435 member locations, comprising 452 locations operated by the Group and 9,983 general member stores, an increase of 679 from the end of the previous consolidated fiscal year.」
The number of pharmaceutical network members increased by 679 from the end of the previous consolidated fiscal year to 10,435. - FY2024-Q2AdvancedAnnual report
「As of 30 September 2023, the pharmaceutical network had 9,374 member locations, comprising 434 locations operated by the Group and 8,940 general member stores, an increase of 462 from the end of the previous consolidated fiscal year.」
The pharmaceutical network membership base increased by 462 from the end of the previous fiscal year to 9,374. - FY2024-Q1AdvancedAnnual report
「As of 30 June 2023, the pharmaceutical network had 9,172 members, comprising 430 Group companies and 8,742 general members, an increase of 260 from the end of the previous fiscal year.」
The pharmaceutical network membership base increased by 260 from 8,912 at the end of the previous fiscal year to 9,172. - FY2023-Q3AdvancedAnnual report
「As of 31 December 2022, the pharmaceutical network had 8,555 member locations, comprising 429 locations operated by the Group and 8,126 general member stores, an increase of 1,154 from the end of the previous consolidated fiscal year.」
The pharmaceutical network membership base expanded from 7,401 at the end of the previous fiscal year to 8,555, a net increase of 1,154. - FY2023-Q2AdvancedAnnual report
「As of 30 September 2022, the pharmaceutical network had 8,173 members, comprising 427 Group companies and 7,746 general members, an increase of 772 from the end of the previous fiscal year.」
The membership base expanded from 7,401 at the end of the previous fiscal year to 8,173, a net increase of 772. - FY2023-Q1AdvancedAnnual report
「As of 30 June 2022, the pharmaceutical network had 7,812 members, comprising 426 Group companies and 7,386 general members, an increase of 411 from the end of the previous fiscal year.」
The membership base increased by 411 from 7,401 at the end of the previous fiscal year to 7,812. - FY2022AdvancedAnnual report
「As of 31 March 2022, the pharmaceutical network had 7,401 members, comprising 425 Group companies and 6,976 general members, an increase of 1,285 from the end of the previous fiscal year.」
The membership base increased by 1,285 from 6,116 at the end of the previous fiscal year to 7,401. - FY2022-Q3AdvancedAnnual report
「As of 31 December 2021, the pharmaceutical network had 424 group members and 6,579 general members, for a total of 7,003 members, an increase of 887 from the end of the previous consolidated fiscal year.」
The pharmaceutical network membership base increased by 887 from the end of the previous consolidated fiscal year to 7,003. - FY2022-Q2AdvancedAnnual report
「As of 30 September 2021, the pharmaceutical network had 419 group members and 6,281 general members, for a total of 6,700 members, an increase of 584 from the end of the previous consolidated fiscal year.」
The pharmaceutical network membership base increased by 584 from the end of the previous consolidated fiscal year to 6,700. - FY2022-Q1AdvancedAnnual report
「As of 30 June 2021, the pharmaceutical network had 6,367 members, comprising 417 Group companies and 5,950 general members, an increase of 251 from the end of the previous fiscal year.」
The pharmaceutical network membership base increased by 251 from the end of the previous consolidated fiscal year to 6,367. - FY2021AdvancedAnnual report
「As of 31 March 2021, the pharmaceutical network had 416 group members and 5,700 general members, for a total of 6,116 members, an increase of 871 from the end of the previous consolidated fiscal year, surpassing a 10% market share.」
Membership reached 6,116, an increase of 871 from the end of the previous fiscal year, marking the new achievement of surpassing a 10% market share. - FY2021-Q3AdvancedAnnual report
「As of 31 December 2020, the pharmaceutical network had 413 group members and 5,332 general members, for a total of 5,745 members, an increase of 500 from the end of the previous consolidated fiscal year.」
The pharmaceutical network membership base increased by 500 from the end of the previous consolidated fiscal year to 5,745. - FY2021-Q2AdvancedAnnual report
「As of 30 September 2020, the pharmaceutical network had 409 group members and 5,227 general members, for a total of 5,636 members, an increase of 391 from the end of the previous consolidated fiscal year.」
The pharmaceutical network membership base increased by 391 from the end of the previous consolidated fiscal year to 5,636. - FY2021-Q1AdvancedAnnual report
「As of 30 June 2020, the pharmaceutical network had 415 group members and 5,202 general members, for a total of 5,617 members, an increase of 372 from the end of the previous consolidated fiscal year.」
The pharmaceutical network membership base increased by 372 from the end of the previous fiscal year to 5,617. - FY2020-Q3AdvancedAnnual report
「As of 31 December 2019, the pharmaceutical network had 421 group members and 4,501 general members, for a total of 4,922 members, an increase of 1,132 from the end of the previous consolidated fiscal year.」
The pharmaceutical network membership base increased by 1,132, from 3,790 at the end of March 2019 to 4,922. - FY2020-Q2AdvancedAnnual report
「As of 30 September 2019, the pharmaceutical network had 419 group members and 4,141 general members, for a total of 4,560 members, an increase of 770 from the end of the previous consolidated fiscal year.」
The pharmaceutical network membership base increased by 770, from 3,790 at the end of March 2019 to 4,560. - FY2020-Q1AdvancedAnnual report
「As of 30 June 2019, the pharmaceutical network had 421 group members and 3,697 general members, for a total of 4,118 members, an increase of 328 from the end of the previous consolidated fiscal year.」
The membership base increased by 328, from 3,790 at the end of March 2019 to 4,118. - FY2019AdvancedAnnual report
「As of 31 March 2019, the pharmaceutical network had 3,790 members, comprising 3,729 dispensing pharmacies and 61 hospitals and clinics, an increase of 1,281 from the end of the previous fiscal year. This substantially exceeded the membership target of 3,200 for the current fiscal year.」
Membership increased by 1,281, from 2,509 at the end of the previous fiscal year to 3,790, exceeding the annual target of 3,200. - FY2019-Q3AdvancedAnnual report
「As of 31 December 2018, the pharmaceutical network had 3,369 dispensing pharmacies and 61 hospitals and clinics, for a total of 3,430 members, an increase of 921 from the end of the previous consolidated fiscal year, reaching the target of 3,200 members for the end of the current period ahead of schedule.」
Membership increased by 921, from 2,509 at the end of the previous consolidated fiscal year to 3,430, reaching the target of 3,200 for the end of the current period ahead of schedule. - FY2019-Q2AdvancedAnnual report
「As of 30 September 2018, the pharmaceutical network had 2,917 dispensing pharmacies and 59 hospitals and clinics, for a total of 2,976 members, an increase of 467 from the end of the previous consolidated fiscal year.」
The pharmaceutical network membership base increased by 467, from 2,509 at the end of the previous fiscal year to 2,976. - FY2019-Q1AdvancedAnnual report
「As of 30 June 2018, the pharmaceutical network had 2,665 dispensing pharmacies and 58 hospitals and clinics, for a total of 2,723 members, an increase of 214 from the end of the previous consolidated fiscal year.」
The membership base increased by 214, from 2,509 at the end of the previous fiscal year to 2,723. - FY2018AdvancedAnnual report
「As of 31 March 2018, the pharmaceutical network had 2,509 members, comprising 2,453 dispensing pharmacies and 56 hospitals and clinics, an increase of 739 from the end of the previous fiscal year. This substantially exceeded the membership target of 2,200.」
The membership base increased by 739, from 1,770 at the end of the previous fiscal year to 2,509, exceeding the target of 2,200. - FY2018-Q3AdvancedAnnual report
「As of 31 December 2017, the pharmaceutical network had 2,238 dispensing pharmacies and 55 hospitals and clinics, for a total of 2,293 members, an increase of 523 from the end of the previous consolidated fiscal year. It took more than 13 years from the launch of the service in September 1999 to reach 1,000 members in January 2013, but it subsequently reached 2,000 members in just 4 years and 8 months.」
Membership reached 2,293, an increase of 523 from the end of the previous fiscal year and also up from 2,012 at the end of the previous quarter. Expansion has continued after reaching 2,000 members. - FY2018-Q2AdvancedAnnual report
「As of 30 September 2017, the pharmaceutical network had 1,974 dispensing pharmacies and 38 hospitals and clinics, for a total of 2,012 members, an increase of 242 from the end of the previous consolidated fiscal year. Membership reached 2,000 in the 19th year since the service began in September 1999.」
Pharmaceutical network membership reached 2,012, an increase of 242 from the end of the previous consolidated fiscal year, passing the 2,000 milestone. - FY2017AdvancedAnnual report
「As of 31 March 2017, the pharmaceutical network had 1,736 dispensing pharmacies and 34 hospitals and clinics, for a total of 1,770 members, an increase of 370 from the end of the previous consolidated fiscal year. Transaction volume for pharmaceuticals also reached a record high, despite the effects of drug price revisions and the leveling off of transaction volume for hepatitis C treatments.」
Membership reached 1,770, an increase of 370 from the end of the previous fiscal year, and pharmaceutical transaction volume also reached a record high. - FY2017-Q3AdvancedAnnual report
「As of 31 December 2016, the pharmaceutical network had 1,635 dispensing pharmacies and 33 hospitals and clinics, for a total of 1,668 members, an increase of 268 from the end of the previous consolidated fiscal year.」
Membership increased from 1,597 at the end of the second quarter to 1,668, a net increase of 268 from the end of the previous consolidated fiscal year. - FY2017-Q2AdvancedAnnual report
「As of 30 September 2016, the pharmaceutical network had 1,564 dispensing pharmacies and 33 hospitals and clinics, for a total of 1,597 members, an increase of 197 from the end of the previous consolidated fiscal year.」
Membership increased from 1,501 at the end of the first quarter to 1,597, a net increase of 197 from the end of the previous consolidated fiscal year. - FY2017-Q1AdvancedAnnual report
「As of 30 June 2016, the pharmaceutical network had 1,464 dispensing pharmacies and 37 hospitals and clinics, for a total of 1,501 members, an increase of 101 from the end of the previous consolidated fiscal year.」
Membership increased from 1,400 to 1,501, a net increase of 101. - FY2016First statedAnnual report
「As of 31 March 2016, the pharmaceutical network had 1,361 dispensing pharmacies and 39 hospitals and clinics, for a total of 1,400 members, an increase of 200 from the end of the previous consolidated fiscal year.」
Actual results at the end of the current period related to measures to expand the network.